Splice Bio, a gene therapy company based on technology developed in the Muir Lab at Princeton University, announced today that it has appointed JeanPhilippe Combal as Chairman of its Board of Director...
Read moreSperogenix Therapeutics, a platform company dedicated to developing and commercializing rare disease therapeutics in China, and Minoryx Therapeutics, a company that specializes in the development of i...
Read moreSplice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a new investment into the Company led by Ysios Capital and joined by Asabys Partner...
Read moreSanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced the completion of a €72.2 million (USD 80.9 million) total...
Read moreEl nuevo biomarcador desarrollado por GlyCardial Diagnostics permitirá detectar previamente un posible ataque de isquemia, y también dar respuesta a la necesidad médica no cubierta de identificar a...
Read moreThe financing was led by new investors Sofinnova Ventures and Ysios Capital, and included existing investors HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management. Since its founding, ...
Read moreTransplant Biomedicals, spin-off del IDIBAPS-Hospital Clínic de Barcelona, ha recibido una inyección de 2,5 millones de euros liderada por Caixa Capital Risc y Kereon Partners para entrar a fase c...
Read moreEl auditorio del Caixaforum de Barcelona ha acogido hoy la entrega de los Premios EmprendedorXXI, una iniciativa impulsada por “la Caixa”, a través de Caixa Capital Risc, y co-otorgada por el Min...
Read moreBiótica obtuvo financiación de la Unión Europea en el último programa SME Instrument de H2020. El proyecto financiado, ULISENS, tiene los objetivos de desarrollar y comercializar un sistema de det...
Read moreLed by new investor Gilde Healthcare , the financing round al so drew participation from existing investors , including Kurma Partners ; Ysios Capital ; Idinvest Partners ; Boehringer Ingelheim Ventur...
Read moreSegún el informe ASEBIO (Asociación Española de Bioempresas) de 2014, España está considerada actualmente como la novena potencia mundial en ciencias de la vida y la quinta a nivel europeo en pro...
Read moreCaixa Innvierte Start is the eighth venture capital fund driven by the ”la Caixa” venture capital firm. With this new vehicle, Caixa Capital Risc now manages an investment volume of 180 million Eu...
Read more